# Gruppo Oncologico del Nord-Ovest: Phase 2 study completed, 16 enrolled (Colorectal Cancer)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | Gruppo Oncologico del Nord-Ovest |
| Sponsor type | Academic and hospital |
| Study | Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC |
| NCT ID | NCT06578559 |
| Phase | Phase 2 |
| Status | completed |
| Conditions | Colorectal Cancer |
| Intervention types | drug |
| Target enrollment | 16 |
| Site countries | Italy |
| Posted | 2024-08-29 |
| Planned start | 2024-07-23 |
| Event | Completed |
| Event date | 2026-10-20 |
| Last update posted | 2026-10-28 |

## Why this score
- Posted in the last two weeks.
- Completed: closeout, analysis and the next study ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06578559). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.